Gilead stock falls 10% after disappointing lung cancer drug trial results
Shares of Gilead took a hit as the stock fell more than 10% on Monday following disappointing results from a late-stage trial of its key lung cancer drug, Trodelvy. The trial failed to significantly extend the lives of patients with…
The Evolving Landscape of Genetic Testing in Oncology
In a recent interview with Targeted Oncology, Dr. Louise Morrell discussed the evolving landscape of genetic testing in oncology and the latest advancements in the field. The use of genetic testing in oncology has seen significant expansion in recent years,…
Critical Drug Shortages Leave Cancer Patients in the U.S. Waiting Over a Year for Life-Saving Medication
Patients with cancer in the United States are facing a critical issue as they are forced to wait over a year for life-saving medication, which costs just $10, due to record-high drug shortages. The average wait time for a drug…
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Genomic Classification and Individualized Prognosis in Multiple Myeloma Published on January 09, 2024 Authors: Francesco Maura, MD, Arjun Raj Rajanna, MSc, Bachisio Ziccheddu, MSc, Alexandra M. Poos, PhD, Andriy Derkach, PhD, Kylee Maclachlan, MD, PhD, Michael Durante, MD, PhD, and…